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Abstract
Aims/hypothesis It is generally accepted that hypoglycaemia can negatively impact the quality of life (QoL) of people living with
diabetes. However, the suitability of patient-reported outcome measures (PROMs) used to assess this impact is unclear. The aim
of this systematic review was to identify PROMs used to assess the impact of hypoglycaemia on QoL and examine their quality
and psychometric properties.
Methods Systematic searches (MEDLINE, EMBASE, PsycINFO, CINAHL and The Cochrane Library databases) were under-
taken to identify published articles reporting on the development or validation of hypoglycaemia-specific PROMs used to assess
the impact of hypoglycaemia on QoL (or domains of QoL) in adults with diabetes. A protocol was developed and registered with
PROSPERO (registration no. CRD42019125153). Studies were assessed for inclusion at title/abstract stage by one reviewer.
Full-text articles were scrutinised where considered relevant or potentially relevant or where doubt existed. Twenty per cent of
articles were assessed by a second reviewer. PROMS were evaluated, according to COnsensus-based Standards for the selection
of health Measurement INstruments (COSMIN) guidelines, and data were extracted independently by two reviewers against
COSMIN criteria. Assessment of each PROM’s content validity included reviewer ratings (N = 16) of relevance, comprehen-
siveness and comprehensibility: by researchers (n = 6); clinicians (n = 6); and adults with diabetes (n = 4).
Results Of the 214 PROMs used to assess the impact of hypoglycaemia on QoL (or domains of QoL), seven hypoglycaemia-
specific PROMS were identified and subjected to full evaluation: the Fear of Hypoglycemia 15-item scale; the Hypoglycemia
Fear Survey; the Hypoglycemia Fear Survey version II; the Hypoglycemia Fear Survey-II short-form; the Hypoglycemic
Attitudes and Behavior Scale; the Hypoglycemic Confidence Scale; and the QoLHYPO questionnaire. Content validity was
rated as ‘inconsistent’, with most as ‘(very) low’ quality, while structural validity was deemed ‘unsatisfactory’. Other measure-
ment properties (e.g. reliability) varied, and evidence gaps were apparent across all PROMs. None of the identified studies
addressed cross-cultural validity or measurement error. Criterion validity and responsiveness were not assessed due to the lack of
a ‘gold standard’ measure of the impact of hypoglycaemia on QoL against which to compare the PROMS.
Conclusions/interpretation None of the hypoglycaemia-specific PROMs identified had sufficient evidence to demonstrate satisfac-
tory validity, reliability and responsiveness. All were limited in terms of content and structural validity, which restricts their utility for
assessing the impact of hypoglycaemia on QoL in the clinic or research setting. Further research is needed to address the content
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Abbreviations
COSMIN COnsensus-based Standards for the
selection of health Measurement
INstruments
EFA Exploratory factor analysis
FH-15 Fear of Hypoglycemia 15-item scale
GRADE Grading of Recommendations
Assessment, Development
and Evaluation
HABS Hypoglycemic Attitudes and
Behavior Scale
HCS Hypoglycemic Confidence Scale
HFS Hypoglycemia Fear Survey
HFS-II Hypoglycemia Fear Survey version II
Hypo-RESOLVE Hypoglycaemia REdefining
SOLutions for better liVEs
PAC Patient Advisory Committee
PROM Patient-reported outcome measure
QoL Quality of life
QoLHYPO QoLHYPO questionnaire
Introduction
Both the experience and the risk of hypoglycaemia can have a
serious negative impact on the quality of life (QoL) of adults
with diabetes [1–8]. Living a life of quality is perhaps the
ultimate goal, so protecting QoL is a daily burden for people
experiencing or at risk of hypoglycaemia, and one that can be
contradictory to the goals of medical therapy [8]. This may
particularly be the case in those who aim for very tight glucose
targets. The extent of this impact on QoL can be assessed
using patient-reported outcome measures (PROMs). PROMs
are questionnaires that can be used in both research and/or
clinical care. PROMs complement objective data (e.g. actual
blood glucose levels) by capturing the individual’s experi-
ences in a quantifiable and standardised manner, across a
range of concepts, e.g. health-related QoL, satisfaction with
treatment or emotional well-being [9, 10].When applied to the
study of hypoglycaemia in diabetes, PROMs can facilitate an
assessment of the psychological and economic burden of
hypoglycaemia, which can be used to determine the value of
therapeutic approaches to reducing hypoglycaemia frequency
and severity.
Given the large number of PROMs available, it can be
challenging to determine which PROM(s) to select for a given
clinical or research purpose. Factors such as response burden
(e.g. mode of administration, number of items [questions]),
type of PROM (generic or condition-specific) and the purpose
of the data collection will influence choice. However, a more
fundamental issue is whether the PROMhas been evaluated as
‘fit for purpose’. This evaluation should include assessment of
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three overall domains (validity, reliability and responsive-
ness), for which consensus-based standards (COnsensus-
based Standards for the selection of health Measurement
Instruments [COSMIN]) can be applied [11]. The COSMIN
methodology and standards derive from widespread interna-
tional expert consensus [11, 12] and have been applied to
other PROM measures [13–17], but not yet to the assessment
of the impact of hypoglycaemia on QoL.
QoL is highly subjective and has been defined in many
ways and most people, intuitively, have an understanding of
what it means to them [18]. Perhaps the simplest definition is
that QoL is a personal evaluation of how good or bad
one’s life is [19]. For the purpose of this review, and
consistent with the general consensus [9], we operationalised
QoL as: (1) a multidimensional construct including compo-
nents such as physical well-being (e.g. pain/discomfort,
mobility, fatigue), psychological well-being (e.g. mood,
fear, confidence) and social well-being (e.g. stigma,
participation) [20]; (2) a subjective construct based on
feelings, values, experiences and priorities (therefore, we
do not include objective measures, or purely functional
performance or assessment instruments); and (3) a
dynamic construct, which changes over time according to
the person’s priorities, experiences and situation.
The objectives of this review were to: (1) identify PROMs
used to assess the impact of hypoglycaemia on QoL in adults
with diabetes; and (2) formally evaluate their content validity,
structural validity and other measurement properties. Our
intention was to provide researchers and clinicians with a
robust evidence base to assist them when selecting PROMs
for this purpose. The review was undertaken as part of the
Hypoglycaemia REdefining SOLutions for better liVEs
(Hypo-RESOLVE) project, an international collaboration of
clinicians, scientists, industry partners and people with diabe-
tes [21].
Methods
We used the updated COSMIN guidance [12, 22–24].
Data sources and searches A protocol was developed and
registered with PROSPERO [25]. A systematic literature
search was conducted during 26–28 November 2018 to iden-
tify published evidence around the four concepts of: (diabetes)
and (hypoglycaemia) and (psychosocial outcomes) and
(measurement properties of measurement instruments).
Databases searched include MEDLINE, EMBASE,
PsycINFO, CINAHL and The Cochrane Library. Terms for
psychosocial outcomes were chosen to include both generic,
‘umbrella’ terms for ‘quality and life’ and ‘well-being’
(sourced from published search filters) and specific psychoso-
cial outcomes of diabetes known to the Hypo-RESOLVE
team (e.g. fear of hypoglycaemia). In order to identify studies
for the present systematic review, a validated search filter
devised for retrieving studies on measurement properties of
instruments in PubMed was used [26]. An example search
strategy is shown in the electronic supplementary material
(ESM) Methods.
Study selection Inclusion criteria consisted of any study
design that included the primary development and/or valida-
tion of a hypoglycaemia-specific PROM used to assess the
impact of hypoglycaemia on QoL in adults diagnosed with
diabetes with any type, e.g. type 1, type 2 and gestational,
and who have experienced hypoglycaemia. Studies of
hypoglycaemia/hypoglycaemic episodes not associated with
diabetes were excluded. Commentaries, reviews, opinion
pieces and any other non-empirical work were also excluded.
Studies were assessed for inclusion at title and abstract stage
by one reviewer (JL). Full-text articles were scrutinised where
considered as relevant or potentially relevant or where doubt
existed. Twenty per cent of studies were assessed by a second
reviewer (JC) to check for consistency. Disagreements were
resolved through discussion.
Data extraction Data extraction included study characteristics
(e.g. language; participant characteristics; recall period; anal-
ysis model), a brief summary of results and measurement
properties of the PROMs. Primary outcomes included
measurement properties of identified PROMs, consistent with
the COSMIN checklist: PROM development; content validi-
ty; structural validity; internal consistency; cross-cultural
validity/measurement invariance; reliability; measurement
error; criterion validity; hypothesis testing for construct valid-
ity; and responsiveness. Definitions of the measurement prop-
erties are detailed in Table 1. In accordance with COSMIN
guidelines, all data relating to PROMmeasurement properties
were extracted independently by two reviewers (JL and JC)
against the respective COSMIN criteria. Discrepancies were
resolved through discussion.
Content validity assessment Content validity is the extent to
which a PROM is deemed to reflect the construct of interest
and, arguably, the most fundamental aspect of scale selection
[27]. The methodological quality of the PROM development
studies and other studies supplementing content validity were
assessed using COSMIN standards [28]. The assessment
involves three steps (see Fig. 1): (1) evaluation of the quality
of the PROM development; (2) evaluation of the quality of
any additional content validity studies on the PROM (if avail-
able); and (3) evaluation of the content validity of the PROM
based on the quality and results of the available studies and the
PROM itself. Steps 1 and 2 result in a rating of each COSMIN
standard ranked on a four-point scale: ‘very good’, ‘adequate’,
‘doubtful’ and ‘inadequate’. Total ratings are then determined
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using the lowest rating for any item for that study (i.e. worst
score counts) [22].
Step 3 consists of three sub-stages. Step 3a incorporates
reviewer ratings of the identified PROMs whereby reviewers
Table 1 Definitions of measurement properties
Measurement property Definition
Content validity The extent to which the items in a PROM are representative of the construct they
are intended to measure
Structural validity The extent to which the items in a PROM reflect the dimensionality of the construct
(i.e. the items form a single [unidimensional] scale or multiple subscales
[a multidimensional scale])
Reliability: internal consistency The extent to which there is consistency of results across items in the PROM
(i.e. within a specified scale or subscale)
Reliability: test–retest The extent to which the PROM yields scores that are reproducible (stable) over
time when there has been no change in the concept being assessed
Measurement error The systematic and random error of a person’s score on the PROM that is not attributed
to changes in the construct to be measured
Criterion validity The extent to which the scores of a PROM reflect the scores of a test or measure
considered to be the ‘gold standard’
Hypothesis testing for construct validity The extent to which the scores of a PROM are consistent with hypotheses. For
example, with regard to internal relationships, relationships to scores of other
instruments or differences between relevant groups. It is based on the assumption
that the PROM is a valid measure of the construct
Responsiveness The ability of a PROM to detect change, as expected, over time in the construct to
be measured when there is a true change in a person’s condition or treatment
Cross-cultural validity The extent to which the measurement properties of the translated or culturally
adapted PROM reflect the performance of the original version of the PROM
STEP 1
Evaluate the quality of PROM 
development
• Assess against 35 COSMIN standards, 
evaluating the quality of PROM design 
and cognitive interviewing/pilot testing
• Results in rating of ‘very good’, 
‘adequate’, ‘doubtful’ or ‘inadequate’
STEP 2
Evaluate the quality of content validity 
studies
• Assess against 31 COSMIN standards, 
evaluating studies that asked patients or 
professionals about: relevance, 
comprehensiveness and/or 
comprehensibility
• Results in rating of ‘very good’, 
‘adequate’, ‘doubtful’ or ‘inadequate’
STEP 3
Evaluate the content validity of 
the PROM
• 3a: PROM development and 
content validity studies are rated 
individually on ten COSMIN 
criteria for content validity. 
Reviewers also provide ratings:
sufficient (+), insufficient (−), 
inconsistent (±) or indeterminate 
(?)
• 3b: The ratings from 3a are 
combined, producing an 
OVERALL rating for relevance, 
comprehensiveness and 
comprehensibility, and content 
validity overall, of sufficient (+), 
insufficient (−), inconsistent (±) or 
indeterminate (?)
• 3c: The ratings produced in 3b are 
accompanied by a grading for 
evidence quality using a modified 
GRADE approach of ‘high’, 
‘moderate’, ‘low’ or ‘very low’
Fig. 1 COSMIN assessment of
content validity
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consider relevance, comprehensiveness and comprehensibili-
ty. We sought ratings from three key stakeholder groups: (1)
researchers (including those with expertise in systematic
reviewing, QoL research and psychological aspects of diabe-
tes) (n = 6); (2) clinicians (n = 6); and (3) adults with diabetes
(n = 4), including two representatives of the Hypo-RESOLVE
Patient Advisory Committee (PAC). All reviewers provided
independent ratings of the PROMs based on several criteria:
(1) the construct of interest (i.e. does the PROM include items
that are relevant in measuring the impact of hypoglycaemia on
QoL?); (2) the population of interest; (3) the context of use of
interest (i.e. is the PROM suitable for use in research and/or
clinical practice?); (4) the appropriateness of response options;
(5) the appropriateness of the recall period; (6) the compre-
hensiveness (i.e. does the PROM assess the impact of
hypoglycaemia on QoL as a whole, or only on select domains
of QoL?); (7) the suitability/clarity of the PROM instructions;
(8) whether PROM items and response options are under-
standable; (9) the appropriateness of PROM item wording;
and (10) the extent to which response options are appropriate
to the question being asked. A majority rating was determined
for each group (researcher, clinician and PAC). The group
ratings were then consolidated to produce an overall reviewer
rating for each PROM. Table 2 details how relevance,
comprehensiveness and comprehensibility were assessed.
Step 3b involves summarising the results of all available stud-
ies to provide an overall rating of relevance, comprehensiveness
and comprehensibility and an overall content validity
rating. This results in an outcome of ‘sufficient’, ‘insufficient’,
‘inconsistent’ or ‘indeterminate’. Finally, in Step 3c, the over-
all ratings determined in Step 3b are accompanied by a grad-
ing of the quality of the evidence using a modified Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) approach [29]. Using the modified GRADE
approach, the quality of evidence is graded as ‘high’, ‘moder-
ate’, ‘low’ or ‘very low’. The GRADE approach uses five
factors to consider the quality of the evidence: risk of
bias, inconsistency, indirectness, imprecision and publi-
cation bias [29]. Detailed information of the rating
process is reported elsewhere [28]. The resultant evaluation
of content validity includes an overall rating of: + (‘satisfac-
tory’); − (‘unsatisfactory’); ± (‘inconsistent’); or ? (‘indeter-
minate’), with a measure of the quality of the evidence to
support the content validity rating (‘high’, ‘moderate’,
‘low’, ‘very low’). A worked example of content valid-
ity rating and scoring is shown in Table 2. Detailed
information on the COSMIN methodology applied is
reported elsewhere [28].
Assessment of other psychometric properties Table 1 defines
each of the psychometric properties assessed. As above, a
COSMIN rating was determined by assessment across
the criteria for measurement properties using the same
rating scale (‘sufficient’, ‘insufficient’, ‘inconsistent’ or
‘indeterminate’). The assessment of the quality of the
evidence was applied using the GRADE approach.
This results in a rating of: + (‘satisfactory’); − (‘unsat-
isfactory’); ± (‘inconsistent’); or ? (‘indeterminate’),
with a measure of the quality of the evidence to
support the structural validity rating (‘high’, ‘moder-
ate’, ‘low’, ‘very low’). Full information on the
COSMIN methodology applied in this review is report-
ed elsewhere [23].
Quality assurance of the review The quality of this reviewwas
assessed against a COSMIN checklist that was designed to
evaluate the quality of systematic reviews of PROMs [30]
(ESM Table 1).
Results
The search returned a total of 3661 unique records, from
which 214 PROMs were identified as used in studies to assess
the impact of hypoglycaemia on QoL or subdomains of QoL
(Fig. 2, Table 3). Of these, 16 PROMs were initially identified
as hypoglycaemia-specific and for consideration in this
review, and nine were subsequently excluded following
further scrutiny of the instruments. PROMs were excluded if
they were: hypoglycaemia symptom measures that assessed
attitudes, awareness and/or attitudes to awareness of symp-
toms (n = 3); related to specific treatments (n = 2); only a
subscale of an overall PROM (n = 2); or not available for full
inspection (n = 2). Consequently, the current review includes
seven hypoglycaemia-specific PROMs that have been used to
assess the impact of hypoglycaemia on QoL or at least one
aspect of QoL: the Fear of Hypoglycemia 15-item scale (FH-
15); the Hypoglycemia Fear Survey (HFS); the Hypoglycemia
Fear Survey version II (HFS-II); the HFS-II short-form; the
Hypoglycemic Attitudes and Behavior Scale (HABS); the
Hypoglycemic Confidence Scale (HCS); and the QoLHYPO
questionnaire (Table 4).
Overall COSMIN assessment of PROMs The overall results of
the COSMIN assessment are shown in Table 5. There are
considerable evidence gaps for the measurement properties
of most of the PROMs. The HFS, HFS-II and QoLHYPO
were the only instruments that could be rated across all the
measurement properties.
Content validity ESM Table 2 summarises the key character-
istics and COSMIN quality assessment of the PROM devel-
opment studies. For four of the six PROMs, there was
evidence that adults with diabetes were involved in item
generation (HFS, HABS, HCS and QoLHYPO). COSMIN








































































































































































































































































































































































































































































































































































































































































































































































































































QoLHYPO), to ‘doubtful’ (HFS-II and HCS), to ‘very good’
(FH-15). The developers of the HFS-II short-form do not
report on content validity, due to the scale being developed
based on existing items in the HFS-II [31].
ESM Table 3 details characteristics of the PROM develop-
ment studies. The overall quality of the PROM development
studies was classified as ‘very good’ (FH-15), ‘inadequate’
(HFS, HABS and QoLHYPO) or ‘doubtful’ (HFS-II and
HCS). Only four of the PROMs provided evidence of concept
elicitation (all of which were of ‘doubtful’ or ‘inadequate’
quality) (HFS, HABS, HCS and QoLHYPO). The COSMIN
rating for the PROM design ranged from ‘inadequate’ (HFS,
HABS and QoLHYPO), to ‘doubtful’ (HFS-II and HCS), to
‘very good’ (FH-15). Two of the PROMs (HFS and
QoLHYPO) reported on content validity. During the develop-
ment of the HFS, health professionals were asked about the
relevance and comprehensiveness of the PROM (‘doubtful’
COSMIN quality rating) [32]. For the QoLHYPO, adults with
diabetes were asked about the comprehensibility, but not rele-
vance, of the PROM (‘doubtful’ COSMIN quality rating)
[33]. Aside from the development studies, no further studies
were identified that independently assessed the content valid-
ity of the PROMs.
ESM Table 4 details the consensus ratings for the three
groups of reviewers (researchers, clinicians, people living
with diabetes), and an overall reviewer consensus rating for
each PROM. FH-15 had an overall reviewer rating of ‘suffi-
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Fig. 2 PRISMA 2009 Flow Diagram: hypoglycaemia-specific PROMs used to assess the impact of hypoglycaemia on QoL
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For two of the PROMs (HFS and QoLHYPO), relevance,
comprehensiveness and comprehensibility ratings resulted in
a combination whereby COSMIN guidance is not explicit,
and, thus, an overall rating could not be applied [28].
Structural validity Eleven studies assessed the structural valid-
ity of the PROMs, all of which were reported in the develop-
ment papers (ESM Table 5). No independent assessments of
the structural validity were identified. Four studies examined
the structural validity of a cultural adaptation/language trans-
lation of the HFS [34–37]. A further study assessed the struc-
tural validity of the short-form of HFS-II [31]. COSMIN qual-
ity ratings of the HFS-Norwegian, HFS-Singapore and HFS
short-form were ‘very good’ and ratings were ‘adequate’ for
the remaining PROMs. The same principles as noted above
were applied to assess the quality of the evidence for these
instruments. The quality of evidence for the HFS-Norwegian,
HFS-Singapore and HFS-II short-form instruments was
assessed as ‘high’. The HFS-Spanish and HFS-Swedish
instruments were assessed as ‘moderate’. Many of the studies
reported exploratory factor analysis (EFA) (rather than the
confirmatory factor analysis required to receive a ‘satisfacto-
ry’ rating). Those studies reporting confirmatory factor anal-
ysis (language versions of the HFS) did so to examine whether
the expected two-factor structure (observed for the original
HFS) fitted their dataset. However, they all rejected this a
priori-defined structure, and therefore went on to explore the
latent structure of the tool using EFA.
Internal consistency reliability Twelve studies were identified
that reported evidence of the internal consistency of the
PROMs [31–33, 35–42]. Some were undertaken by the instru-
ment developers and some were independent assessments
(ESM Table 6). Most studies [32, 33, 35, 38, 39, 41, 42] had
an ‘adequate’ COSMIN quality rating. Four studies had a
‘very good’ COSMIN quality rating [31, 36, 37, 40].
Reliability (test–retest) Six studies were identified that
assessed the test–retest reliability of a PROM measure.
Three of the studies were conducted by the instrument devel-
opers (FH-15, HFS-II and QoLHYPO). The remaining studies
Table 4 PROMs identified that have been used to assess the impact of hypoglycaemia on QoL (or its subdomains) in people with diabetes


















































QoLHYPO Not stated Not stated (13) Not reported Never, rarely, sometimes,
often, always. 0–4 scale
0–52 Spain No—Spanish
only version
Table 3 Type and number of PROMs identified in title and abstract sift
Type of PROM measure Number of PROMs
Designed for completion by children/adolescents 22








were assessments of the language versions of the HFS instru-
ment (ESM Table 7). Four studies had an ‘adequate’
COSMIN quality rating [32, 33, 35, 39]. Two studies had a
‘very good’ COSMIN quality rating [36, 37].
Hypothesis testing for construct validity Eleven studies
reported on hypothesis testing for construct validity (ESM
Table 8) [31, 33–35, 37–39, 41, 42]. Of these, eight were
comparing with other outcome measurement instruments
(convergent validity) [31, 33–35, 37, 39, 41, 42]. These were
HFS-II, HFS-Spanish, HFS-Singapore, HFS-Sweden, HFS-II
short-form, HABS, HCS and QoLHYPO. Five studies includ-
ed comparisons between subgroups (discriminative or known-
groups validity) [37–39, 41, 42]. These were FH-15, HFS-II,
HFS-Singapore, HABS and HCS instruments.
Other psychometric properties No studies were found to
demonstrate evidence for cross-cultural validity, measurement
error, criterion validity or responsiveness.
Discussion
This systematic review has summarised and critically evalu-
ated published evidence on the psychometric characteristics of
PROMs used to assess the impact of hypoglycaemia on QoL
in adults with diabetes using COSMIN methodology. Our
intention was to provide an evidence base that would help
researchers and clinicians when selecting PROMs, based on
the robust and comprehensive consensus-based COSMIN
criteria. We identified seven PROMs that had been developed
to assess the subjective impact of hypoglycaemia on QoL or a
subdomain of QoL.
None of the PROMs included in this review had a ‘high’
rating for content validity (in relation to assessing the impact
of hypoglycaemia on QoL), which is arguably the most
important measurement property of a PROM [28, 43]. All
had ‘inconsistent’ COSMIN ratings for content validity, but
the quality of the evidence to support those ratings was greater
for the HFS and QoLHYPO. To that end, there is some
support to recommend the use of HFS and QoLHYPO instru-
ments in research studies and/or clinical practice. However, it
is important to acknowledge the conceptual framework from
which these two instruments were developed, and how this
diverges from our operationalisation of the concept of QoL
(i.e. multidimensional, subjective and changing over time).
The HFS was developed to measure fear of hypoglycaemia
through two subscales—behaviour and worry. Fear is argu-
ably a very specific aspect of the psychological subdomain of
QoL. Furthermore, the developers were not explicit in describ-
ing the target population for the instrument (i.e. their sample
included people with ‘insulin-dependent’ diabetes, but it is




























































































































































































































































































































































































































































































































































































































diabetes, and whether it is also applicable to people who
manage their diabetes without insulin but experience
hypoglycaemia). While the content of the QoLHYPO instru-
ment includes items that assess various domains of QoL (e.g.
social relationships, mood, daily activities), it was designed
for use only by people with type 2 diabetes. Furthermore,
there have been no translations beyond the original Spanish
version. Consequently, the format and layout of the
QoLHYPO is not clear for English-speaking researchers,
and the developers provide no information on domains.
Further investigation would be required to determine the suit-
ability of the QoLHYPO instrument in measuring the impact
of hypoglycaemia in people with type 1 diabetes and in other
language groups.
We have included details of psychometric properties of the
PROMs identified as part of the original literature search.
However, it is plausible that additional papers have also
reported psychometric properties for one or more of the
included PROMs (particularly in intervention studies). To that
end, the information on measurement properties reported here
should not be considered exhaustive. We did not adopt the
approach taken by (some of) the PROM authors to consider
HbA1c as the ‘gold standard’ in the assessment of criterion
validity and criterion approach to responsiveness. Studies
have shown that HbA1c it is not a reliable indicator of whether
an individual experiences hypoglycaemia [44, 45], nor a
surrogate for QoL [46], nor of the impact or burden of
hypoglycaemia. Advances in glucose monitoring technolo-
gies are continually changing our understanding of diabetes
and are contributing to a better understanding of the lived
experience of diabetes and hypoglycaemia. Consequently, it
may be appropriate in future studies to consider ‘time in
range’ or ‘time in hypoglycaemia’ as a marker for the
impact of hypoglycaemia on QoL—but the extent to which
this will reflect the subjective experience has yet to be eluci-
dated. In the absence of an agreed ‘gold standard’, it is not
possible to determine the assessment of any criterion valid-
ity or criterion approach to responsiveness for any PROM.
In this systematic review, we followed the robust and
comprehensive guidance developed by the COSMIN initia-
tive [23, 28]. However, it is not without its limitations. The
assessment of content validity and psychometric performance
of PROMs is determined by taking the lowest rating of any
standard in the criteria (i.e. the ‘worst score counts’ principle)
[22, 28]. This means that a study could be rated as ‘very good’
or ‘good’ on all but one criterion; however, the overall rating
could be affected by a ‘doubtful’ or ‘inadequate’ rating, thus
reducing the overall score to ‘doubtful’ (or ‘inadequate’). The
omission of one key component in reporting (such as whether
interviews were recorded and transcribed verbatim) can result
in a lower overall content validity rating, which could be
argued as overly harsh and should be recognised as a limita-
tion of the COSMIN approach. Where appropriate within this
review, we consistently rated in favour of the PROM (rather
than assuming the worst). Another limitation of the COSMIN
approach was identified in the guidance for determining
content validity ratings of studies. Here we noted that there
was no information on how to determine overall content valid-
ity rating with the combinations achieved. We have docu-
mented our approach; however, if the review was to be repli-
cated, others may opt to ‘down-grade’ the overall content
validity rating. Furthermore, as part of the content validity
assessment, we sought to include the opinion of stakeholders.
The COSMIN guidance does not advise on how to ratify
ratings should there be conflicting opinions between or within
stakeholder groups.
It should be noted that some of the PROMs included within
this review are legacy or ‘first generation’ measures; that is,
they were developed at a time when there were no internation-
al standards for instrument development methods, so these
were either not reported, or reported selectively or in little
detail. Similarly, the way in which PROMs are developed
has changed over time [27]. It is now more common to report
the methodological steps undertaken during the instrument
development phase. The COSMIN ratings should therefore
be interpreted with a degree of caution, and do not provide
evidence that the instrument development was not rigorous or
that the instruments are not ‘fit for purpose’, but rather expose
an absence of key evidence.
While there is published evidence of studies that report
hypoglycaemia to negatively impact upon QoL [1–8], we have
identified that those that utilise hypoglycaemia-specific PROMs
have inadequate reliability and validity for this specific purpose.
Thus, the current literature on the impact of hypoglycaemia on
QoL is limited (if not flawed) and needs to be
interpreted with caution. Given that the content validity
of the instruments was lacking, it is plausible that
hypoglycaemia impacts individuals in ways that are
currently not being measured. It may be that the items
within the instruments are no longer relevant (e.g. due to
changes in diabetes treatments, monitoring, society, language
use), or that the items are not comprehensive enough to fully
capture the ways in which hypoglycaemia affects adults in the
modern world.
In conclusion, none of the PROMs identified had sufficient
evidence to demonstrate satisfactory content validity, i.e. they
do not assess the impact of hypoglycaemia on QoL in adults
living with diabetes. Furthermore, most were also limited in
their published evidence of reliability, validity and responsive-
ness. There is an urgent need to follow contemporary guid-
ance [27, 47–49] to develop new instruments that can assess
the impact of hypoglycaemia on QoL.
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